First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
B7-H1 Antigen
/ antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Humans
Lung Neoplasms
/ drug therapy
Nivolumab
/ administration & dosage
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Randomized Controlled Trials as Topic
Anti-PD-1/PD-L1
Chemotherapy
Immunotherapy
Management
Meta-analysis
Non-small-cell lung cancer
PD-L1
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
08
08
2019
accepted:
28
10
2019
pubmed:
7
11
2019
medline:
19
2
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
Single-agent anti-PD-1/PD-L1 clinical efficacy against < 1% PD-L1-expressing non-small-cell lung cancers (NSCLCs) is controversial. This meta-analysis examined randomized-trial data comparing first-line PD-1/PD-L1-inhibitor + chemotherapy (CT) vs CT alone for advanced < 1% PD-L1 NSCLCs. Outcome measures included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR). IMpower (atezolizumab + CT), Keynote (pembrolizumab + CT) and CheckMate (nivolumab + CT) trials included 2037 NSCLCs (1246 PD-L1-negative; 791 < 1% PD-L1 expression). Anti-PD-1/PD-L1 + CT was significantly associated (hazard ratio [95% confidence interval]) with prolonged OS (0.75 [0.63-0.89]; p = 0.0008) and PFS (0.72 [0.65-0.80]; p < 0.0001), and higher ORR (odds ratio 2.06 [1.50-2.83]; p < 0.0001). First-line anti-PD-1/PD-L1 + CT combination appears superior to CT alone for advanced, < 1% PD-L1-expressing NSCLCs for OS, PFS and ORR.
Identifiants
pubmed: 31686247
doi: 10.1007/s00432-019-03070-3
pii: 10.1007/s00432-019-03070-3
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
B7-H1 Antigen
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
atezolizumab
52CMI0WC3Y
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-448Références
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Immunother Cancer. 2018 Dec 22;6(1):155
pubmed: 30577837
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Immunotherapy. 2019 Mar;11(4):311-320
pubmed: 30678553
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Ann Oncol. 2019 Feb 1;30(2):219-235
pubmed: 30608567